This guideline includes statements and recommendations based on available, high-level evidence about the use of bisphosphonates in early breast cancer. The guideline provides health professionals with information designed to help them make management recommendations for improved patient outcomes. Cancer Australia also develops information specifically for consumers about the diagnosis and treatment of early breast cancer.
A clinical practice guideline developed by Cancer Australia*
This document supplements information contained in the Clinical practice guidelines for the management of early breast cancer, 2nd edition 2001.
Incorporates published evidence to June 2011
Endorsed by:
- Breast Surgeons of Australia and New Zealand Inc.
- The Faculty of Radiation Oncology - The Royal Australian and New Zealand College of Radiologists
- Medical Oncology Group of Australia Inc. (MOGA)
- The Royal College of Pathologists of Australia (RCPA)
Document identification:
ISBN Online: 978-1-74127-167-6
© Cancer Australia 2011
* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.
| Guideline Topic | Early breast cancer |
| Cancer Types | Breast cancer |
This resource was developed, reviewed or revised more than 5 years ago and may no longer reflect current evidence or best practice.